Krystal Biotech, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Krystal Biotech, Inc. (KRYS) had Lessee, Operating Lease, Liability, to be Paid, Year One of $1.92 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-08-03
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $1.92M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.92M.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.86M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $1.86M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2026-06-30 | $1.92M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.92M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $1.86M 10-K · filed 2026-02-17 |
| 2025-09-30 | $1.86M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $1.87M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $1.88M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.28M 10-K · filed 2025-02-19 |
| 2024-09-30 | $1.28M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $1.28M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $1.28M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $1.54M 10-K · filed 2024-02-26 |
| 2023-09-30 | $1.54M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $1.54M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.54M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.65M 10-K · filed 2023-02-27 |
| 2022-09-30 | $1.64M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $1.51M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.51M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.09M 10-K · filed 2022-02-28 |
| 2021-09-30 | $1.09M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $1.05M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $686.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.43M 10-K · filed 2021-03-01 |
| 2020-09-30 | $1.36M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $3.03M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |